Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

508.80INR
19 Apr 2018
Change (% chg)

Rs-3.10 (-0.61%)
Prev Close
Rs511.90
Open
Rs514.00
Day's High
Rs515.10
Day's Low
Rs507.45
Volume
536,814
Avg. Vol
593,046
52-wk High
Rs675.55
52-wk Low
Rs433.15

Latest Key Developments (Source: Significant Developments)

Beijing Science Sun Pharmaceutical sees FY 2018 Q1 net profit up 10 pct to 40 pct
Monday, 2 Apr 2018 

April 2 (Reuters) - Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ>:Says it sees FY 2018 Q1 net profit to increase by 10 percent to 40 percent, or to be 49.8 million yuan to 63.4 million yuan.Says FY 2017 Q1 net profit was 45.3 million yuan .  Full Article

Sun Pharmaceutical Industries Gets U.S. FDA Nod Of ILUMYA (Tildrakizumab-Asmn)
Wednesday, 21 Mar 2018 

March 21 (Reuters) - Sun Pharmaceutical Industries Ltd ::CO GETS U.S. FDA APPROVAL OF ILUMYA (TILDRAKIZUMAB-ASMN) FOR TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS.  Full Article

Sun Pharmaceutical Industries Says U.S. FDA Issued Form 483 With 3 Observations For Halol Facility
Friday, 23 Feb 2018 

Feb 23 (Reuters) - Sun Pharmaceutical Industries Ltd ::SUN PHARMACEUTICAL INDUSTRIES -U.S. FDA CONDUCTED GMP INSPECTION OF HALOL FACILITY (GUJARAT, INDIA) FROM FEBRUARY 12-23, 2018.AT CONCLUSION OF INSPECTION, AGENCY ISSUED A FORM 483, WITH THREE OBSERVATIONS.SUN PHARMACEUTICAL INDUSTRIES - CO PREPARING RESPONSE TO FDA OBSERVATIONS, TO BE SUBMITTED WITHIN 15 BUSINESS DAYS.  Full Article

Sun Pharma Industries Says Qtrly US Finished Dosage Sales Down 35 Pct
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS US FINISHED DOSAGE SALES DURING QUARTER AT US$ 328 MILLION, DOWN 35 PERCENT OVER Q3 LAST YEAR.  Full Article

India's Sun Pharmaceutical Industries Dec-Qtr Consol Profit Down 75 Pct
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Sun Pharmaceutical Industries Ltd ::DEC QUARTER CONSOL NET PROFIT AFTER TAX 3.65 BILLION RUPEES VERSUS PROFIT OF 14.72 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR DEC QUARTER CONSOL PROFIT WAS 9.12 BILLION RUPEES.DEC QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 66.54 BILLION RUPEES VERSUS 79.25 BILLION RUPEES LAST YEAR.SAYS CONSOL EXCEPTIONAL TAX EXPENSE IN QUARTER 5.13 BILLION RUPEES.  Full Article

Sun Pharmaceutical Industries Announces Settlement Of Patent Litigation For Generic Linzess In U.S.
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS CO'S UNITS HAVE REACHED AN AGREEMENT WITH IRONWOOD PHARMACEUTICALS, INC. AND ALLERGAN PLC.ANNOUNCES SETTLEMENT OF PATENT LITIGATION FOR GENERIC LINZES IN US.COMPANIES TO GRANT CO'S UNITS LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S FROM FEB 1, 2031 OR EARLIER UNDER CIRCUMSTANCES.ADDITIONAL DETAILS REGARDING THE SETTLEMENT WERE NOT DISCLOSED..  Full Article

Allergan, Ironwood Announce Settlement With Sun Pharma
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Allergan Plc ::IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION.SAYS PER SETTLEMENT TERMS, IRONWOOD, CO TO GRANT UNITS OF SUN PHARMA LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 1, 2031​.SAYS ‍ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED​.SAYS IRONWOOD PHARMACEUTICALS, CO ANNOUNCED COMPANIES REACHED AN AGREEMENT WITH WHOLLY-OWNED UNITS OF SUN PHARMACEUTICAL INDUSTRIES.SAYS ‍AS A RESULT OF SETTLEMENT, ALL HATCH-WAXMAN LITIGATION BETWEEN COMPANIES AND SUN PHARMA REGARDING LINZESS PATENTS TO BE DISMISSED​.  Full Article

Sun Pharmaceutical Industries Announces U.S FDA Acceptance Of NDA For OTX-101
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Sun Pharmaceutical Industries Ltd ::ANNOUNCES U.S FDA ACCEPTANCE OF NDA FOR OTX-101.  Full Article

Beijing Science Sun Pharmaceutical obtains high-tech enterprise recognition and to enjoy tax preference
Tuesday, 26 Dec 2017 

Dec 26(Reuters) - Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ>:Says it was recognized as high-tech enterprise, and to enjoy a tax preference of 15 percent for three years .  Full Article

Sun Pharma Industries MD says no new updates on Halol; awaiting FDA re-inspection of plants‍​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Sun Pharmaceutical Industries managing director Dilip Shanghvi says::No new updates on halol, awaiting FDA reinspection of plants‍​.  Full Article

BRIEF-Sun Pharmaceutical Industries' Unit Raises Stake In Ranbaxy Malaysia

* UNIT RAISED STAKE IN RANBAXY MALAYSIA VIA FURTHER PURCHASE OF 394,404 SHARES OF RANBAXY MALAYSIA